Cancer Research Meeting Calendar Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allen, J. D.
Right arrow Articles by Schinkel, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allen, J. D.
Right arrow Articles by Schinkel, A. H.
[Cancer Research 60, 5761-5766, October 15, 2000]
© 2000 American Association for Cancer Research

Experimental Therapeutics

Extensive Contribution of the Multidrug Transporters P-Glycoprotein and Mrp1 to Basal Drug Resistance1

John D. Allen, Remco F. Brinkhuis, Liesbeth van Deemter, Jan Wijnholds and Alfred H. Schinkel2

Divisions of Experimental Therapy [J. D. A., R. F. B., A. H. S.] and Molecular Biology [L. v. D., J. W.], The Netherlands Cancer Institute, 1066CX Amsterdam, The Netherlands

Despite accumulating evidence that multidrug resistance transporter proteins play a part in drug resistance in some clinical cancers, it remains unclear whether the relatively low levels of multidrug resistance transporter expression found in most untreated tumors could substantially affect their basal sensitivity to antineoplastic drugs. To shed light on this problem, the drug sensitivities of wild-type mouse cell lines were compared with those of lines in which the Mdr1a and Mdr1b genes encoding P-glycoprotein (P-gp) were inactivated and lines in which the Mrp1 gene was inactivated in addition to Mdr1a and Mdr1b. These models permit a clean dissection of the contribution of each transporter to drug resistance at expression levels similar to those in normal tissues and avoid complications that might arise from previous exposure of cell lines to drug selection. For substrate drugs, we found that these contributions can indeed be very substantial. Lines lacking functional P-gp were, on average, markedly more sensitive to paclitaxel (16-fold), anthracyclines (4-fold) and Vinca alkaloids (3-fold). Lines lacking both P-gp and Mrp1 were (compared with wild-type lines) hypersensitive to an even broader array of drugs, including epipodophyllotoxins (4–7-fold), anthracyclines (6–7-fold), camptothecins (3-fold), arsenite (4-fold) and Vinca alkaloids, especially vincristine (28-fold). Thus, even very low levels of P-gp and Mrp1 expression that may be difficult to detect in tumors could significantly affect their innate sensitivity to a wide range of clinically important substrate drugs. An implication is that the use of resistance reversal agents to sensitize drug-naive tumors may be appropriate in more cases than is presently appreciated.




This article has been cited by other articles:


Home page
 Mol. Interv.Home page
J. S. Lagas, M. L.H. Vlaming, and A. H. Schinkel
Pharmacokinetic Assessment of Multiple ATP-binding Cassette Transporters: The Power of Combination Knockout Mice
Mol. Interv., June 1, 2009; 9(3): 136 - 145.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. K. Raj, J. Mu, H. Jiang, J. Kabat, S. Singh, M. Sullivan, M. P. Fay, T. F. McCutchan, and X.-z. Su
Disruption of a Plasmodium falciparum Multidrug Resistance-associated Protein (PfMRP) Alters Its Fitness and Transport of Antimalarial Drugs and Glutathione
J. Biol. Chem., March 20, 2009; 284(12): 7687 - 7696.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Hopper-Borge, X. Xu, T. Shen, Z. Shi, Z.-S. Chen, and G. D. Kruh
Human Multidrug Resistance Protein 7 (ABCC10) Is a Resistance Factor for Nucleoside Analogues and Epothilone B
Cancer Res., January 1, 2009; 69(1): 178 - 184.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C.-P. Wu, S. Shukla, A. M. Calcagno, M. D. Hall, M. M. Gottesman, and S. V. Ambudkar
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter
Mol. Cancer Ther., December 1, 2007; 6(12): 3287 - 3296.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. R. Gerstner and R. L. Fine
Increased Permeability of the Blood-Brain Barrier to Chemotherapy in Metastatic Brain Tumors: Establishing a Treatment Paradigm
J. Clin. Oncol., June 1, 2007; 25(16): 2306 - 2312.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Haber, J. Smith, S. B. Bordow, C. Flemming, S. L. Cohn, W. B. London, G. M. Marshall, and M. D. Norris
Association of High-Level MRP1 Expression With Poor Clinical Outcome in a Large Prospective Study of Primary Neuroblastoma
J. Clin. Oncol., April 1, 2006; 24(10): 1546 - 1553.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Green, P. Soderkvist, P. Rosenberg, G. Horvath, and C. Peterson
mdr-1 Single Nucleotide Polymorphisms in Ovarian Cancer Tissue: G2677T/A Correlates with Response to Paclitaxel Chemotherapy
Clin. Cancer Res., February 1, 2006; 12(3): 854 - 859.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. J. Dilda, A. S. Don, K. M. Tanabe, V. J. Higgins, J. D. Allen, I. W. Dawes, and P. J. Hogg
Mechanism of Selectivity of an Angiogenesis Inhibitor From Screening a Genome-Wide Set of Saccharomyces cerevisiae Deletion Strains
J Natl Cancer Inst, October 19, 2005; 97(20): 1539 - 1547.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. Pavek, G. Merino, E. Wagenaar, E. Bolscher, M. Novotna, J. W. Jonker, and A. H. Schinkel
Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 144 - 152.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Kalin, J. Fernandes, S. Hrafnsdottir, and G. van Meer
Natural Phosphatidylcholine Is Actively Translocated across the Plasma Membrane to the Surface of Mammalian Cells
J. Biol. Chem., August 6, 2004; 279(32): 33228 - 33236.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Cisternino, C. Mercier, F. Bourasset, F. Roux, and J.-M. Scherrmann
Expression, Up-Regulation, and Transport Activity of the Multidrug-Resistance Protein Abcg2 at the Mouse Blood-Brain Barrier
Cancer Res., May 1, 2004; 64(9): 3296 - 3301.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. D. Allen, S. C. van Dort, M. Buitelaar, O. van Tellingen, and A. H. Schinkel
Mouse Breast Cancer Resistance Protein (Bcrp1/Abcg2) Mediates Etoposide Resistance and Transport, but Etoposide Oral Availability Is Limited Primarily by P-glycoprotein
Cancer Res., March 15, 2003; 63(6): 1339 - 1344.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Z. P. Lin, D. R. Johnson, R. A. Finch, M. G. Belinsky, G. D. Kruh, and A. C. Sartorelli
Comparative Study of the Importance of Multidrug Resistance-associated Protein 1 and P-Glycoprotein to Drug Sensitivity in Immortalized Mouse Embryonic Fibroblasts
Mol. Cancer Ther., October 1, 2002; 1(12): 1105 - 1114.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. D. Allen, S. C. Jackson, and A. H. Schinkel
A Mutation Hot Spot in the Bcrp1 (Abcg2) Multidrug Transporter in Mouse Cell Lines Selected for Doxorubicin Resistance
Cancer Res., April 1, 2002; 62(8): 2294 - 2299.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. D. Allen, A. van Loevezijn, J. M. Lakhai, M. van der Valk, O. van Tellingen, G. Reid, J. H. M. Schellens, G.-J. Koomen, and A. H. Schinkel
Potent and Specific Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter in Vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C
Mol. Cancer Ther., April 1, 2002; 1(6): 417 - 425.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. D. Allen and A. H. Schinkel
Multidrug Resistance and Pharmacological Protection Mediated by the Breast Cancer Resistance Protein (BCRP/ABCG2)
Mol. Cancer Ther., April 1, 2002; 1(6): 427 - 434.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Zelcer, T. Saeki, G. Reid, J. H. Beijnen, and P. Borst
Characterization of Drug Transport by the Human Multidrug Resistance Protein 3 (ABCC3)
J. Biol. Chem., November 30, 2001; 276(49): 46400 - 46407.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. Duesberg, R. Stindl, and R. Hehlmann
Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome reassortments catalyzed by aneuploidy
PNAS, September 5, 2001; (2001) 201398998.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. Liu, H. Chen, D. S. Miller, J. E. Saavedra, L. K. Keefer, D. R. Johnson, C. D. Klaassen, and M. P. Waalkes
Overexpression of Glutathione S-Transferase II and Multidrug Resistance Transport Proteins Is Associated with Acquired Tolerance to Inorganic Arsenic
Mol. Pharmacol., August 1, 2001; 60(2): 302 - 309.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. R. Johnson, R. A. Finch, Z. P. Lin, C. J. Zeiss, and A. C. Sartorelli
The Pharmacological Phenotype of Combined Multidrug-Resistance mdr1a/1b- and mrp1-deficient Mice
Cancer Res., February 1, 2001; 61(4): 1469 - 1476.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. Duesberg, R. Stindl, and R. Hehlmann
Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome reassortments catalyzed by aneuploidy
PNAS, September 25, 2001; 98(20): 11283 - 11288.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.